GLP-1s and BaroStim Neo revisited, a new drug for transthyretin amyloid CM, clopidogrel vs ASA years after PCI and stent, and statins are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. GLP-1s and Obesity, BaroStim Neo Revisited
FDA Expands Label for CVRx Barostim System in HF https://www.medscape.com/viewarticle/fda-expands-label-cvrx-barostim-system-hf-2023a1000wsx
JAMA Cardiology Special Communication – BDP https://jamanetwork.com/journals/jamacardiology/fullarticle/2810726
II. ATTR Cardiomyopathy
ATTRibute-CM NEJM paper https://www.nejm.org/doi/full/10.1056/NEJMoa2305434
Circulation Review of TTR https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.111.078915
ATTR-ACT (Tafadimis) https://www.nejm.org/doi/10.1056/NEJMoa1805689
III. Clopidogrel vs ASA Years After PCI
Long-term Clopidogrel Has Advantages After Coronary Stenting
https://www.medscape.com/viewarticle/long-term-clopidogrel-has-advantages-after-coronary-stenting-2024a10000c8
Stop DAPT Original Trial
STOP DAPT at 5 Years https://doi.org/10.1016/j.jacc.2023.10.013
Network Meta-analysis of P2Y12-I vs ASA https://doi.org/10.1016/j.jcin.2022.08.009
IV. Statin Use
Statin Use Remains Low for At-Risk Patients
https://www.medscape.com/viewarticle/999043
Annals of Internal Medicine Observational Study https://doi.org/10.7326/M23-1915
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
